Dopamine receptor D1- and D2-agonists do not spark brown adipose tissue thermogenesis in mice

Francesca-Maria Raffaelli1, Julia Resch1, Rebecca Oelkrug1

  • 1Department of Molecular Endocrinology, Institute for Endocrinology and Diabetes, University of Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Germany.

Scientific Reports
|November 20, 2020
PubMed

Insights

Dopamine receptor agonists do not effectively activate brown adipose tissue (BAT) thermogenesis for obesity treatment. Studies show limited effects, suggesting D1 and D2 receptors in BAT are not viable targets for weight management.

Area of Science:

  • Metabolism and Endocrinology
  • Pharmacology
  • Obesity Research

Background:

  • Brown adipose tissue (BAT) thermogenesis is a key target for treating obesity and diabetes.
  • Dopamine receptor signaling shows potential for activating BAT in vitro, but in vivo relevance is unclear.

Purpose of the Study:

  • To investigate the in vivo and ex vivo effects of dopamine receptor agonists on BAT thermogenesis.
  • To determine if D1 and D2 receptors in BAT are viable targets for obesity treatment.

Main Methods:

  • Peripheral administration of D1-agonist (SKF38393) and D2-agonist (Sumanirole) in mice.
  • Infrared thermography and molecular analyses (Ucp1, Dio2 mRNA) of BAT.
  • Ex vivo studies on BAT explants.

Main Results:

  • Acute agonist administration caused transient changes in BAT temperature.
  • Repeated administration did not yield lasting effects on BAT thermogenesis.
  • No direct effect of agonists on Ucp1 or Dio2 mRNA expression in BAT explants.

Conclusions:

  • Investigated dopamine agonists do not produce lasting, physiologically relevant effects on BAT thermogenesis.
  • D1 and D2 receptors in brown adipose tissue are unlikely targets for obesity treatment via BAT activation.

Related Concept Videos

Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.4K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
2.4K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.9K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.1K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
945
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.6K